Experimental immunotherapy targets metastatic breast cancer
WEBFeb 1, 2022 · Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).
TROPION-Breast01: Dato-DXd Significantly Delayed Progression in …
WEB2 days ago · FDA D.I.S.C.O. Burst Edition: FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer. Accessed August 30, 2024. Bardia A, Krop IE, Kogawa T, et al. Datopotamab deruxtecan in advanced or metastatic HR+/HER2– and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study.
Breast cancer metastasis on/off switch revealed - Stanford News
WEBDec 20, 2023 · Researchers uncover on/off switch for breast cancer metastasis. New research from Stanford and the Arc Institute could lead to a new and more effective immunotherapy and help clinicians better predict patient response to existing medicines.
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 · The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike precision was...
Breast cancer treatment: Drug Kisqali approval expanded for …
WEB2 days ago · The drug was found to reduce the risk of a patient's breast cancer coming back by 25%. The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to ...
Promising New Treatment for Some Patients with Metastatic Breast Cancer
WEBMay 30, 2024 · Breast cancer that has spread to other parts of the body (metastatic) is particularly hard to treat. New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer.
ASCO 2024: Improving Outcomes in Metastatic Breast Cancer
WEBJun 18, 2024 · Research presented at the ASCO Annual Meeting 2024 highlighted treatments that may improve outcomes for patients with metastatic breast cancer.
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer …
WEBMar 9, 2024 · Developments across second-line targeted therapies for patients with endocrine-sensitive hormone receptor (HR)–positive, HER2-negative metastatic breast cancer supplement the first-line...
NIH study advances personalized immunotherapy for metastatic breast cancer
WEBFeb 1, 2022 · An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes ...
Skip to content